Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin

Next Previous
X
Search
Trial Profile

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms MAGELLAN
  • Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin; Janssen Research & Development

    • Most Recent Events

    • 07 Apr 2022 Results of a pooled analysis (MAGELLAN and MARINER trials data) assessed that the patients with major bleeding but not those with non-major clinically relevant bleeding, would be at an increased risk of all-cause mortality published in the Circulation
    • 23 Jan 2020 Results from MARINER and MAGELLAN trials published in the Thrombosis and Haemostasis.
    • 18 Nov 2019 Results (N= 16,496), post hoc analysis of the data pooled from two trials (MAGELLAN and MARINER Trials) assessing the efficacy of the extended thromboprophylaxis post to hospital discharge presented at the American Heart Association Scientific Sessions 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top